Brendan D. Curti

2 ta ish

Providence Portland Medical Center

1. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

   Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio +26

   Maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.047644

2. Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

   Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye +12

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.296875